Greenlight Citital报告说,在Coya治疗治疗自发免疫和炎症的临床试验中取得了进展。 Greenlight Capital reports progress in Coya Therapeutics' clinical trials for autoimmune and inflammatory disease treatments.

Greenlight Capital是Coya治疗公司的主要投资者,它介绍了该公司的最新进展情况,着重介绍了该公司针对自发性免疫和炎症的疗法进展。 Greenlight Capital, a major investor in Coya Therapeutics, provided an update on the company’s progress, highlighting advancements in its pipeline of therapies targeting autoimmune and inflammatory diseases. 该公司注意到在对Coya的主要候选人进行临床试验方面取得的积极进展,强调改善病人的结果和继续支持该公司的研究与发展努力。 The firm noted positive developments in clinical trials for Coya’s lead candidate, emphasizing improved patient outcomes and continued support for the company’s research and development efforts. 没有披露任何新的财务细节。 No new financial details were disclosed.